

## Neurizon Completes Entitlement Offer

*Not for release to US wire services or distribution in the United States*

### Highlights:

- **\$5.88 million raised through a well-supported Entitlement Offer, including strong participation from Eligible Shareholders and oversubscriptions**
- **Shareholder support reinforces confidence in Neurizon's strategy and long-term vision, with 73.5 million new shares issued under the Entitlement Offer**
- **Proceeds strengthen disciplined execution, supporting regulatory, manufacturing and operational activities and the timely completion of the HEALEY ALS Platform Trial**
- **The Company remains on track to commence dosing in the HEALEY ALS Platform Trial in Q1 CY2026**

**27 January 2026 – Melbourne Australia:** Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the results of the Company's pro-rata non-renounceable entitlement offer announced by the Company on 23 December 2025 ("Entitlement Offer"), which closed on Wednesday, 21 January 2026.

Under the Entitlement Offer, eligible shareholders had the opportunity to acquire two (2) new fully paid ordinary shares in the Company ("Shares") for every five (5) Shares held as at 7.00pm on 30 December 2025 ("Record Date") at an offer price of \$0.08 per new Share.

The Entitlement Offer was well supported by eligible shareholders who applied for 59,524,761 new Shares under the Entitlement Offer, and an additional 13,983,956 new Shares under the oversubscription facility, raising \$5,880,697.36 (before costs).

The Entitlement Offer forms part of Neurizon's funding strategy to support execution of its clinical development priorities, with a primary focus on advancing NUZ-001 within the HEALEY ALS Platform Trial. As part of this program, the Company continues to progress regulatory, manufacturing and operational activities in preparation for first patient dosing in the HEALEY ALS Platform Trial, targeted for Q1 CY2026. This strategy reflects the Company's commitment to progressing treatments with urgency and rigour for people living with ALS and other neurodegenerative diseases.

### Entitlement Offer Results

	Shares	Proceeds
<b>Total number of new Shares available under the Entitlement Offer</b>	214,316,313	\$17,145,305.04
<b>Total number of new Shares applied for by eligible shareholders under the Entitlement Offer</b>	59,524,761	\$4,761,980.88
<b>Total number of additional new Shares applied for by eligible shareholders under the oversubscription facility</b>	13,983,956	\$1,118,716.48
<b>TOTAL</b>	<b>73,508,717</b>	<b>\$5,880,697.36</b>
<b>Total number of Shortfall Shares</b>	140,807,596	\$11,264,607.68

The Company is expected to issue 73,508,717 new Shares under the Entitlement Offer on Thursday, 29 January 2026, with such Shares expected to commence trading on ASX on a normal settlement basis on Friday, 30 January 2026.

Sergio Duchini, Chairman of the Board and Non-Executive Director at Neurizon, commented: "We are grateful for the strong support shown by our shareholders through the Entitlement Offer, which reinforces confidence in Neurizon's strategy, execution discipline and long-term vision. Importantly, as we have consistently communicated to the market

in prior announcements, Neurizon remains fully funded to execute and complete its participation in the HEALEY ALS Platform Trial. The proceeds from this Entitlement Offer further strengthen our balance sheet and provide additional flexibility as we progress regulatory, manufacturing and operational activities. The Board remains firmly focused on disciplined delivery, capital stewardship and urgency of execution, as we work to advance NUZ-001 through the HEALEY trial and pursue meaningful, patient-centred outcomes for people living with ALS and other neurodegenerative diseases."

The Company reserves the right to issue any new Shares not issued in the Entitlement Offer ("Shortfall Shares") to new investors or existing shareholders within 3 months of close of the Entitlement Offer at a price no less than the offer price of \$0.08 per Share, in accordance with the terms of the Entitlement Offer. This provides flexibility to support the ongoing execution of the Company's clinical development strategy. The allocation of Shortfall Shares will be within the complete discretion of Neurizon, having regard to factors such as Neurizon's desire for an informed and active trading market, its desire to establish a wide spread of shareholders, the size and type of funds under management of particular investors, the likelihood that particular investors will be long-term shareholders, and any other factors Neurizon considers appropriate.

The Company wishes to thank all eligible shareholders that have participated in the Entitlement Offer.

Neurizon remains focused on disciplined execution of its clinical development, with near-term priorities centred on advancing NUZ-001 through the HEALEY ALS Platform Trial. The Company believes the strong support shown by shareholders reflects confidence in its mission to bring forward next-generation treatments that have the potential to make a meaningful difference for patients and their families.

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

**Neurizon Therapeutics**

Lidija Damjanovic  
Marketing & Corporate Affairs  
Email: [lidija@neurizon.com](mailto:lidija@neurizon.com)  
Phone: +61 (0) 425 700 504

**Australia Investor Relations**

Henry Jordan  
Six Degrees Investor Relations  
Email: [henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
Phone: +61 (0) 431 271 538

**U.S. Investor Relations**

Matthew Selinger  
Integrous Communications  
Email: [mselinger@integcom.us](mailto:mselinger@integcom.us)  
Phone: +1 415-572-8152

**Not an offer of securities**

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

**About Neurizon Therapeutics Limited**

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

**Neurizon Investor Hub**

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.

This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit  
<https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited

For personal use only